Won Ki Kang
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (42)
Figure S6. (A) UMAP embedding of single cell transcriptomes obtained from all samples in this trial. Labeled are canonical cell types separated by tumor v.s. normal tissue, and by timepoint. (B) Heatmap and (C) UMAP embeddings showing marker gene expression for broad cell types in (A). (D) Broad cell type composition per sample across tumor and normal tissue. (E) Cell type proportions from scSeq data by timepoint in tumor and normal tissue excluding HER2+ patients. (F) Cell type proportions from scSeq data by timepoint and TCGA classification excluding HER2+ patients.
Year:
2024
(A) Swimmers plot of patient response and duration in the described clinical trial. (B) Scatter plot showing temporal course of tumor response measured by RECIST for all patients in the reported clinical trial. (C) Progression free survival (PFS) and (D) overall survival (OS) for all patients in the reported clinical trial separated by fast and slow progressors.
Year:
2024
Figure S7. (A) UMAP embedding of single cell transcriptomes from epithelial cells obtained from all samples in this trial. Shown are UMAP embeddings with expression of key epithelial genes. (B) UMAP embeddings color coded by predicted annotation of tumor cell v.s. normal cell using Numbat.
Year:
2024
Figure S27. Boxplots showing usage of T cell cNMF programs in T cells of fast and slow progressors (A) post-chemotherapy (FU1) and (B) post-immunotherapy (FU2). (C) Expression of CD39, CD103, CXCL13, 4-1BB and GITR in single CD8 T cells segregated by timepoint (BL, FU1, FU2) and by fast versus slow progressing patients. Statistical comparison performed using a Wilcoxon signedrank test.
Year:
2024
Figure S25. (A) UMAP embedding of single cell transcriptomes of all T cells obtained from all samples in this trial. Labeled are granular T cell subsets separated by tumor v.s. normal tissue, and by timepoint. (B) UMAP embeddings showing marker gene expression for T cell subsets in (A).
Year:
2024
Figure S21. (A) Change in M2 ratio from baseline to FU1 in patients with decreased or increased stromal proportions. (B) Proportion of stromal cells in patient samples from fast and slow progressing patients split by timepoint. (C) UMAP embedding of single cell transcriptomes of all stromal cells obtained from all samples in this trial. Labeled are granular stromal cell types separated by tumor v.s. normal tissue, and by timepoint. (D) UMAP embeddings showing marker gene expression for granular stromal cell types in (C). (E) Proportion of myofibroblasts in patient samples from fast and slow progressing patients split by timepoint.
Year:
2024
Figure S15. Heatmap showing pairwise correlation of gene program activities across all patient samples at baseline using the 90th percentile of patient-level program activity in epithelial, myeloid, T, NK and stromal cells. Hierarchical clustering was performed to identify clusters of co-varying proteins.
Year:
2024
Figure S9. (A) Cell type proportions from scSeq shown by individual patient split by individual high-level cell types across timepoints, color coded by fast vs slow progression status. (B) Cell type proportions from scSeq data by timepoint and fast vs slow progressor status including only GS and CIN patients.
Year:
2024
Figure S3. (A) Enrichment of gene expression signatures for TME subtypes using bulk RNA-sequencing data for all patient samples at baseline and after chemotherapy (follow-up 1; FU1). (B) Pathway enrichment analysis on differentially expressed genes comparing bulk RNA-seq profiles for samples obtained pretreatment (baseline) and samples obtained after 1 cycle of chemotherapy (FU1). (C) Plots demonstrating change in immune related gene signatures (Treg, Treg trafficking, Th2, immune checkpoints, M2 macrophages, pro-tumorgenic cytokines) after chemotherapy treatment. Lines connect samples obtained from the same patient. Statistical comparison performed using a Wilcoxon signed-rank test. (D) Quantification of CD8+ cell abundance using immunohistochemistry (IHC) at baseline and after chemotherapy (FU1) in 12 patient samples. Statistical comparison performed using a Wilcoxon signed-rank test.
Year:
2024
Figure S16. Heatmap showing pairwise correlation of gene program activities across all patient samples post-chemotherapy (FU1) using the 90th percentile of patient-level program activity in epithelial, myeloid, T, NK and stromal cells. Hierarchical clustering was performed to identify clusters of co-varying proteins.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (10)
Byung-Hoon Min
Professor
Samsung Medical Center
Ryan Park
Assistant Professor
The University of Texas MD Anderson Cancer Center
Samuel Klempner
Associate Professor
Massachusetts General Hospital
Hyuk Lee
Sungkyunkwan University School of Medicine
Seung Tae Kim
Sungkyunkwan University School of Medicine
Tae Jun Kim
Sungkyunkwan University School of Medicine
Matthew Strickland
Harvard University
Jeeyun Lee
Samsung Medical Center
Kyoung Mee Kim
Sungkyunkwan University
Woong-Yang Park
Professor
Sungkyunkwan University
Make your next move.
Prepare your application
Review drafts before you send them.